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A Patient Decision Support Tool for Hepatitis C Virus and
CKD Treatment
Nerissa George, AnnMarie Liapakis, Kevin M. Korenblat, Tingting Li, David Roth, Jerry Yee,
Kevin J. Fowler, Lehman Howard, Jingxia Liu, and Mary C. Politi
Rationale & Objective: Patient education and
decision support tools could facilitate decisions
around the timing of antiviral therapy in patients
living with both hepatitis C virus (HCV) infection
and chronic kidney disease (CKD). We previously
developed a tool through the HELP (Helping
Empower Liver and Kidney Patients) study. This
article evaluates the preliminary efﬁcacy and usability of the tool among participants with both
HCV infection and CKD.
Study Design: Pre-post study pilot evaluation.
Setting & Participants: Participants were at least
18 years old, were English speaking, and had a
diagnosis of chronic HCV infection and CKD;
they were seen in CKD clinics, dialysis units,
and/or hepatology and liver transplantation
clinics.
Intervention: Electronic patient decision support
tool.
Outcomes: Participants’ change in knowledge,
certainty about choice, decision self-efﬁcacy,
patients’ treatment preferences, and tool usability.
Results: 70 participants were recruited; 56 of 70
(80.0%) completed study procedures. Nearly all
(51/56; 91.1%) requested paper-based study
procedures despite the electronic design of the

tool. Participants reported that they were most
worried about the following treatment factors: (1)
cost of drugs to treat HCV infection, (2) how
their HCV infection affected their CKD, and (3)
wait times for a kidney transplant. After using the
decision tool, participants had signiﬁcantly higher
HCV infection and CKD knowledge (mean
posttest percent of questions answered
correctly = 65.74% vs pretest percent of
questions
answered
correctly = 53.44%;
P < 0.001) and more certainty about choice
(mean
posttest = 3.13
vs
pretest = 2.65;
P = 0.05). There were no signiﬁcant changes in
decision self-efﬁcacy (mean posttest = 86.62 vs
pretest = 84.68; P = 0.48).
Limitations: Single-site pilot study to explore preliminary tool efﬁcacy and usability.
Conclusions: This study suggests that a decision
tool may support informed patient-centered
choices among patients with HCV infection and
CKD. Future studies should evaluate ways to
improve care decisions in a larger sample using
both paper-based and electronic materials.
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A

pproximately 3.5 million US individuals are infected
with the hepatitis C virus (HCV).1 This prevalence is
increasing in part due to increased intravenous drug use in
the United States associated with the continuing opioid
epidemic.2 HCV infection can lead to serious complica-

Editorial, p. 150
tions, such as hepatocellular carcinoma, cirrhosis, and/or
liver failure.3 Patients with HCV infection are also 27%
more likely to have or develop chronic kidney disease
(CKD) than patients without HCV infection.4 The combination of HCV infection and CKD can lead to kidney failure, kidney transplant failure, poor quality of life, and
adverse mental health.3,5-11
Fortunately, current HCV oral direct-acting antiviral
(DAA) treatment regimens are highly effective. Patients
with HCV infection who take DAAs demonstrate a sustained virologic response of >95%, meaning that HCV is
undetectable beyond 24 weeks posttreatment.12,13 DAA
regimens are more effective with fewer side effects than
previously available therapies such as interferon and
200
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ribavirin.13 In addition, there are US Food and Drug
Administration–approved DAAs that are safe for individuals with both HCV infection and CKD. Patients
treated with DAA regimens demonstrated significantly
fewer side effects with newer14,15 compared with older
therapies, which were prescribed to as few as 1% of patients with comorbid HCV infection and CKD due to
concerns about severe side effects.16
Despite the effectiveness of DAAs, patients who have
both HCV infection and CKD, especially advanced CKD,
face challenging decisions about when to start HCV treatment. Typically, patients spend 3 to 5 years on the waitlist
for an HCV-negative deceased donor kidney transplant,
and this wait time can be longer in certain United Network
for Organ Sharing regions.17 With improvements in HCV
treatments, patients with advanced CKD can consider a
kidney from an HCV-viremic donor, leading to shorter
wait times for a kidney transplant. The median wait time
for a kidney from an HCV-viremic donor is 58 days.18
A shorter wait time for a kidney transplant can shorten
the time that patients spend on dialysis therapy, decreasing
mortality and improving quality of life.19 Dialysis is a
Kidney Med Vol 1 | Iss 4 | July/August 2019
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time-consuming kidney replacement therapy with often
burdensome side effects that can affect patients’ ability to
maintain their social engagement and employment status.20 Patients on dialysis more frequently report depressive symptoms and reduced quality of life compared with
patients who receive a kidney transplant.20 HCV-positive
dialysis patients experience higher rates of mortality
when compared with noninfected patients with advanced
CKD.19,21 In some cases, because of shortened wait times
associated with accepting a kidney from an HCV-“positive” (antibody positive and/or viremic) donor, patients
may be able to receive a pre-emptive kidney transplant
before it is necessary to initiate dialysis.
However, in some regions such as the northwestern
United States, HCV-positive kidneys are not readily available.22 Patients’ health status and preferences may affect
whether patients with decreased kidney function choose to
initiate HCV treatment before receiving a kidney transplant. The development of liver fibrosis due to HCV may
necessitate treating HCV infection first; for patients with
severe hepatic fibrosis, treating HCV infection to slow the
progression of disease may be a higher priority than
receiving a kidney transplant.12 Patients with early CKD
might not qualify for kidney transplantation and could
benefit from HCV treatment, which can slow the progression of both their liver and kidney disease. In some
cases, insurance coverage, other medication use, and comorbid conditions23 can affect patients’ HCV infection and
CKD treatment decisions.
Given the complexity of the decisions about when and
how to treat HCV infection and CKD, consistent communication between patients and their clinicians can facilitate
evidence-informed
preference-consistent
treatment
choices.18,24,25 Patient education and decision support
tools could help patients learn about CKD and HCV and
navigate through discussions about CKD and HCV treatment with their clinicians, including primary care physicians, nephrologists, hepatologists, and transplant
surgeons. Increasing the understanding of patients with
HCV infection and CKD of the treatment risks and benefits
and considerations about treatment timing could increase
their confidence in their treatment choices.
We developed a patient education and decision support
tool with an advisory board, which consists of patients,
nephrologists, and hepatologists through the HELP
(Helping Empower Liver and Kidney Patients) study.26
This tool provides: (1) plain language information about
treatment options for HCV infection and CKD; (2) education that is tailored to a user’s self-reported prior treatments, current stages of CKD and liver fibrosis, and
additional medical conditions; (3) an assessment to elicit
users’ values that may influence their choice of treatment;
and (4) a printable summary page that can facilitate
patient-clinician discussions about treatment needs, values,
and questions.
The tool was not designed to replace patients’ discussions with their clinicians, but to help patients prepare for
Kidney Med Vol 1 | Iss 4 | July/August 2019

these discussions. This report describes the findings of
pilot testing the decision support tool.
METHODS
Participants and Study Procedures
Eligible participants were at least 18 years old, could read
and understand English, and had a diagnosis of chronic
HCV infection (any genotype) and CKD (estimated
glomerular filtration rate < 60 mL/min/1.73 m2 for ≥3
months) in their medical record. Recruitment occurred
between September 2017 and August 2018. A research
staff member assessed participants’ preliminary eligibility
for the study by screening medical records in CKD clinics,
dialysis units, and hepatology and liver transplantation
clinics. In the clinics in which the study team was
approved to recruit, clinicians were also able to refer patients to the study directly. The research coordinator then
approached eligible patients in person during an on-site
medical appointment or by telephone.
After completing informed consent, participants had the
option to complete the study procedures using an online
version of the decision tool and study measures, a paperbased version of both, or a combination of online and
paper-based versions of the study materials based on their
preference. The paper-based version of the tool entailed
printing each section of the electronic version that participants would have viewed based on their CKD stage
(Item S1). Participants had the choice to complete the
study materials in person with the research coordinator
present or at home. Participants completed the pretest
survey before going through the decision tool and a
posttest survey after using the decision tool. Participants
received a $20 gift card for their time spent completing the
study.
This study was approved by the Human Research Protection Office at Washington University (HRPO number
201707154) and was registered on clinicaltrials.gov
(NCT03426787). All authors had access to the study
data, and reviewed and approved the final manuscript.
Measures
Knowledge
The research team developed 8 questions based on information essential for deciding on treatment choices, understanding HCV infection and CKD, the health effects of
both diseases, and understanding risks and benefits of
treatment options. Response options included true, false,
or unsure. The total number of correct responses were
calculated; each correct response counted as 1 and each
incorrect or unsure response counted as zero. Item S2
shows the knowledge questions.
Decisional Conﬂict and Certainty About Choice

The 4-item validated SURE (Sure of myself, Understand
information, Risk-benefit ratio, and Encouragement)
Decisional Conflict Scale27 was used to assess whether
201
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participants have enough information to make a choice,
are clear about their values for risks and benefits of their
choice, and believe that they have enough support to make
a choice. Items were scored 1 (yes) or zero (no). Higher
values indicate more certainty about choice.
Decision Self-efﬁcacy

The low literacy version of the validated Decision Selfefficacy Scale28 was used to measure participants’
perceived self-confidence in making a treatment decision
and how confident they feel taking actions involved in
making an informed choice. Responses include not
confident, a little confident, or very confident. Higher
values indicate more confidence in one’s decision-making
ability.
Usability

The 10-item validated System Usability Scale (SUS)29
examined the usability of the tool; minor modifications
were made to make the wording relevant to this context.
The measure has 1 of 5 responses that range from strongly
agree to strongly disagree. Higher values indicate greater
usability. A SUS score higher than 68 indicates adequate
usability of the tool.
Demographics

Demographic variables including age, sex, education level,
race, ethnicity, household income, and insurance status
were collected from each participant through self-report or
the electronic medical record, when available.
Clinical Characteristics

From the medical record, we collected participants’ CKD
staging, stage of liver fibrosis, HCV status/length of
diagnosis and genotype, dialysis treatment status, and the
presence of comorbid conditions, such as diabetes, hypertension, human immunodeficiency virus (HIV) infection, and/or cardiovascular disease.
Health Literacy

The validated Single Item Literacy Screener30 measured
participants’ health literacy levels. A score greater than 2
on the 5-point scale indicates limited health literacy; a
score of 2 or less on the 5-point scale indicates adequate
health literacy.
Preferred Decision Role

The validated Control Preference Scale31 assessed the degree of involvement that patients prefer in their treatment
decisions. Participants were asked to select 1 of 5 statements that best describes their preference level for decision
control ranging from active to collaborative to passive roles
in treatment decision making.
Financial Toxicity

We used 2 items from the validated Comprehensive Score
for Financial Toxicity (COST)32 measure to assess the
202

financial impact of patients’ medical conditions. Items are
rated on a 4-point Likert scale. In the full 11-item measure,
scores may range from 0 to 44, with lower scores indicating higher financial toxicity. Using the 2 items that we
selected from the measure to reduce participant burden
completing the study procedures, total scores in our
sample could range from 0 to 8.
Data Analysis Plan
We calculated descriptive statistics for all variables. To
examine our primary hypotheses, we performed a paired t
test to examine the differences between before and after
using the decision tool in our primary outcomes
(knowledge, decisional conflict, and decision selfefficacy). Separate mixed models using both fixed and
random effects explored the relationship between age,
race, education, decision role preference, and clinical
characteristics on changes in our primary outcomes
(knowledge, decisional conflict, and decision self-efficacy)
before and after using the tool. Separate analyses were built
with decisional conflict and decision self-efficacy as outcomes, controlling for age, sex, self-reported HCV treatment status, presence of fibrosis, dialysis treatment status,
and decision role preference. In addition, separate analyses
were built with knowledge as an outcome, controlling for
health literacy along with age, sex, self-reported HCV
treatment status, presence of fibrosis, dialysis treatment
status, and decision role preference.

RESULTS
Eighty-eight participants were approached: 70 of 88
(79.5% response rate) enrolled, and 56 of 70 (80.0%
completion rate) completed the study procedures,
including pre- and posttool surveys. There were no demographic differences between study completers and
noncompleters, but noncompleters were more likely to
have additional health conditions (Table S1). The final
sample of completed data included 56 participants with an
average age of 61.0 years, ranging from 40 to 74 years
(Table 1). Most (82.1%) participants identified as African
American or black and had relatively low reported
household incomes (60.7% were <$15,000; Table 1).
Nearly all (51/56; 91.1%) participants chose to complete
the study procedures using a paper-based modality. More
than half (32/56; 57.1%) of the participants opted to
complete the study procedures at home rather than in the
clinic. The mean COST score was 4.80 (median, 5; range,
0-8), indicating moderate financial toxicity. About 64.8%
of patients preferred taking an active or shared role in their
health decisions and 35.2% of patients preferred taking a
passive role. When reporting what matters most to their
decision and treatment plan (scale ranges from 0%-100%),
participants reported that they were most concerned with:
(1) their ability to pay for the cost of drugs used to treat
HCV infection (mean importance, 55%; median, 50%),
(2) how their HCV infection affects their CKD (mean
Kidney Med Vol 1 | Iss 4 | July/August 2019
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Table 1. Participant Characteristics
Age, y
≤50
51-64
≥65
Sex
Male
Female
Education level
Less than or some
high school
High school diploma
or GED
Tech training or
certiﬁcation
Some college
≥College degree
Income level
<$15,000
≥$15,000 but <$45,000
≥$45,000
Prefer not to answer
Race
African American or black
Caucasian or white
Native American or
Alaskan Native
Mixed
Type of insurance coverage
Private
Governmental (Medicaid,
Medicare, & VA/TriCare)
Uninsured
Financial toxicitya
Mean (median)
Range
Health literacy
Adequate
Limited
HCV treatment status
Naive
Received
CKD staging and treatment status
1-3
4-5
Hemodialysis
Fibrosis staging
0-1
2-3
4
Not in medical record
Additional health conditions
None
1b
2c
3d

Table 1 (Cont'd). Participant Characteristics
60.95 ± 6.58 (40-74)
3 (5.36%)
36 (64.29%)
17 (30.36%)
35 (62.50%)
21 (37.50%)
22 (39.29%)
13 (23.21%)
5 (8.93%)
11 (19.64%)
5 (8.93%)
34 (60.71%)
10 (17.86%)
4 (7.14%)
8 (14.29%)
46 (82.14%)
7 (12.50%)
1 (1.79%)
2 (3.57%)
2 (3.57%)
52 (92.86%)
2 (3.57%)
4.80 (5.00)
0-8
32 (57.14%)
24 (42.86%)
21 (37.50%)
35 (62.50%)
19 (33.93%)
5 (8.93%)
32 (57.14%)
22 (39.29%)
7 (12.50%)
19 (33.93%)
8 (14.29%)
6 (10.71%)
14 (25.00%)
25 (44.64%)
11 (19.64%)
(Continued)
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Study completion modality
Paper
Online
Hybrid

51 (91.07%)
4 (7.14%)
1 (1.79%)

Note: N = 56. Values expressed as number (percent) or mean ± standard deviation (range) unless otherwise noted.
Abbreviations: CKD, chronic kidney disease; GED, General Education Development; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; VA, Veterans Affairs.
a
Lower score indicates worse ﬁnancial burden.
b
Patients had only high blood pressure or HIV infection.
c
Patients had a combination of 2 of the following health conditions: diabetes,
high blood pressure, heart disease, or HIV infection.
d
Patients had a combination of 3 of the following health conditions: diabetes,
high blood pressure, heart disease, or HIV infection.

importance, 52%; median, 50%), and (3) the wait time
for a kidney transplant in their region (mean importance,
46%; median, 50%).
Changes in Primary Outcomes
After using the patient education and decision support tool,
participants had significantly higher HCV infection and CKD
knowledge (mean posttest percent of questions answered
correctly, 65.74% vs pretest percent of questions answered
correctly, 53.44%; P < 0.001) and more certainty about
their choice as measured using the SURE scale for decisional
conflict (mean posttest, 3.13 vs pretest, 2.65; P = 0.05;
Table 2). There were no significant changes in decision selfefficacy (mean posttest, 86.62 vs pretest, 84.68; P = 0.48;
Table 2). Mixed-effect models showed that the improvement in knowledge scores remained significant after
adjusting for self-reported HCV treatment status (P = 0.05)
and health literacy (P = 0.03). The improvement in decisional conflict scores did not remain significant after controlling for covariates in the mixed-effect models
(Table S2). No other potential covariates were statistically
significantly related to our primary outcomes.
Usability
The decision tool scored an average of 69.86 ± 20.43
(standard deviation; range, 27.50-100), indicating
adequate usability. Almost all (42/54; 77.8%) participants
found the tool to be easy to use and 40 of 53 (75.5%) felt
very confident using it. More than half (34/53; 64.2%)
found the pages of the tool well integrated and 31 of 54
(57.4%) reported they would like to use the tool again.
About a third (20/53; 37.7%) of participants thought that
they needed to learn many things before they could use the
tool, and 19 of 54 (35.8%) thought that they might need
technical support to be able to use the tool.

DISCUSSION
Overall, this study suggests that the decision support tool
may improve decision quality among patients with HCV
infection and CKD. Among participants in this pilot study,
after using the decision tool, patients had higher
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Table 2. Paired t Test Bivariate Analysis of Primary Outcomes
Knowledgea
Decisional conﬂictb
Decision self-efﬁcacyc

Pretest
53.44 ± 21.66 (12.50-100)
2.65 ± 1.39 (0-4)
84.68 ± 17.24 (22.73-100)

Posttest
65.74 ± 22.80 (12.50-100)
3.13 ± 1.40 (0-4)
86.62 ± 18.88 (13.64-100)

Mean Difference (95% CI)
12.30 (18.95 to 5.65)
0.47 (0.94 to 0.01)
1.94 (7.41 to −3.54)

P
<0.001
0.05
0.48

Note: N = 54. Values expressed as mean ± standard deviation (range) unless otherwise noted.
Abbreviation: CI, conﬁdence interval.
a
Percent correct of answered questions; possible range 0% to 100%.
b
Higher values indicate more certainty in their choice.
c
Higher values indicate more conﬁdence in one’s ability to make a choice; possible range 0% to 100%.

knowledge about HCV and CKD and more certainty about
HCV infection and CKD treatment choices. Increasing patients’ knowledge and certainty about their choices could
help them become more engaged in discussions with their
clinicians regarding their HCV infection and CKD treatment. Some patients in the study who had not yet received
HCV treatment described feeling more prepared to talk to
their physician about HCV infection and CKD treatment
options. Well-informed patients who participate in their
health care decisions may show increased self-care behaviors and decreased stress associated with their
diagnosis.20,33
However, there were no significant changes in participants’ decision self-efficacy. Many participants had high
baseline levels of confidence making HCV infection and
CKD treatment decisions before viewing the decision tool.
Most participants also reported taking an active or shared
responsibility decision-making role. These results should
be examined in a larger study among participants with
varying baseline levels of confidence in the decisionmaking process.
In addition, some persistent knowledge gaps could be
clarified in future versions of the tool. For example,
although knowledge improved after using the tool, on
average, individuals only answered w65% of the questions correctly. The most common incorrect responses
were to questions about whether DAAs have fewer side
effects than past medications used to treat HCV infection
and the possible benefits of treating HCV infection before
receiving a kidney transplant. HCV treatment status and
health literacy were related to lower knowledge scores. It is
possible that the paper-based version with static content,
which was unable to provide interactive learning modules,
contributed to this lower score than is often seen in decision support tool evaluations. Future iterations of the
decision support tool should focus on ways to improve
participants’ understanding of key details about treatment.
Clinicians should also be prepared to reinforce key messages about treatment options in person.
Importantly, the usability score indicates adequate usability per measure guidelines, but the observed scores
were lower than some usability scores in our past work.34
This somewhat lower SUS score might be due to participants’ preferences for receiving information on paper. The
decision support tool was intended for electronic use to
facilitate dissemination and incorporate patients’ clinical
characteristics information. We anticipate that members of
204

the care team (eg, nurses, medical assistants, or others) can
provide patients with this information upon check in,
before seeing a clinician for a health care visit to discuss
treatment options. It could also be used after a health care
visit to supplement the conversation that clinicians have
with patients so they can review what was discussed and
share it with family members or caregivers. Future studies
might consider multiple modalities of information delivery
(eg, online vs on paper, at home vs in the clinic) given the
preferences of this population.
Some participants who preferred to participate in the
study from their homes were hard to reach to complete the
study procedures after enrollment. Given the demographics of this sample, who were mostly men with
lower incomes than those in the average population, access
to and comfort with the internet and/or research overall
may have presented a challenge to study completion.35-37
Although we were available to meet participants in person,
additional barriers to meeting in person (eg, transportation
and time) might have influenced patients’ ability to
complete the study procedures.
When asked about values influencing choices, participants expressed that they were most concerned about their
ability to pay for the cost of drugs used to treat HCV
infection. Health insurance may or may not fully cover
HCV treatment costs and might be associated with high
copayments or out-of-pocket costs before deductibles.
Participants were also concerned with how to balance
treatment for both HCV infection and CKD; decision tools
addressing both conditions may be particularly useful for
this population. Finally, uncertainty regarding the wait
times for patients considering kidney transplantation
added additional stress as they considered their treatment
options. Helping patients communicate these concerns to
their clinicians may facilitate patient-centered conversations about HCV infection and CKD treatment.
Strengths of this study include a personalized plainlanguage decision tool that when delivered electronically
is tailored to patients’ clinical characteristics. The tool
development process included the input of stakeholders,
including patients and multiple clinicians from various
specialties relevant to HCV infection and CKD treatment.
However, the results of this study should be interpreted
within the context of some limitations. Given the small
sample and pilot study design, the reported observations
can be interpreted as preliminary results supporting future
larger studies of the decision tool. This project was also a
Kidney Med Vol 1 | Iss 4 | July/August 2019
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single-site study. Although participants may represent the
demographics of individuals affected by HCV infection and
CKD in the region, they might not be generalizable across
other regions. Future larger studies could consider evaluating the decision tool using a multisite randomized trial
with a more racially and socioeconomically diverse
population.
Overall, the patient education and decision support tool
may improve decision quality and patient engagement in
their CKD and HCV infection care decisions. In past
studies, patients with CKD and HCV infection have reported lack of sufficient patient-provider communication
about their condition and treatment options.38 Uncertainty
about the diseases and the quality of treatment can affect
patients’ care decisions.39 Patients may choose therapies
that positively improve their health outcomes and those
that align with their values when they better understand
the risks and benefits of options.40 Future studies should
continue to evaluate ways to improve care decisions
among this population.
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